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Atrial fibrillation increases the risk of stroke. Dronedarone has been shown to
reduce the composite of hospitalizations due to cardiovascular events or
death, in subjects with intermittent atrial fibrillation or flutter. Recently,
dronedarone has been tested in subjects with permanent atrial fibrillation
15in the PALLAS (permanent atrial fibrillation outcome study using dronedar-
one on top of standard therapy) trial, and this clinical trial is evaluated in
this paper. PALLAS was stopped early as there was an increased incidence of
cardiovascular events in the dronedarone group. Dronedarone also increased
the rate of hospitalizations in PALLAS. As a result of PALLAS, dronedarone
20has been contraindicated in permanent atrial fibrillation. The outcomes of
PALLAS highlight a discontinuity between dronedarone actions in permanent
and intermittent atrial fibrillation. The mechanism(s) underlying the detri-
mental effects of dronedarone in permanent atrial fibrillation are unknown
at present and need to be investigated.
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1. Introduction
Atrial fibrillation is the cardiac arrhythmia most commonly seen in the clinic; its
30incidence increases with age, reaching nearly 10% for those over 80 years old [1,2].
The risk of atrial fibrillation is associated with hypertension, coronary artery disease,
valvular heart disease, heart failure, thyrotoxic heart disease and diabetes [1,2]. Atrial
fibrillation can be associated with haemodynamic dysfunction, tachycardia-
induced cardiomyopathy, systemic thromboembolism, and a marked reduction in
35quality of life [1]. Atrial fibrillation increases the risk of death, mainly due to throm-
boembolic events, with 15 -- 25% of all strokes in the USA being due to atrial fibril-
lation [1]. The condition tends to be progressive: with time, paroxysms of atrial
fibrillation give way to persistent and ultimately permanent atrial fibrillation [1,2].
Antiarrhythmic drugs are administered to patients with atrial fibrillation in
40whom pharmacological strategies for acute rate control are warranted and can be
used to terminate episodes (pharmacological cardioversion) and to prevent arrhyth-
mia recurrence [3]. By blocking potassium channels, amiodarone slows repolariza-
tion, thus prolonging the action potential and the refractoriness of myocardium,
and this is effective at reducing ventricular arrhythmia in atrial fibrillation [4]. Amio-
45darone exhibits a comparatively good cardiac safety profile but has extra-cardiac side
effects including thyrotoxicity, which is due to the presence of iodine in its chemical
structure [4].
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Dronedarone (Multaq) was developed by sanofi-aventis as a
structurally related non-iodinated compound that may confer
50 some of the benefits of amiodarone without side effects arising
from its iodination [5]. However, dronedarone is not without
problems. Thus, in the ANDROMEDA (antiarrhythmic
trial with dronedarone in moderate to severe CHF evaluating
morbidity decrease) trial, dronedarone increased the deaths
55 in subjects with severe heart failure (class III and IV,
together with a left ventricular ejection fraction, LVEF,
of £ 35%) [6], and thus dronedarone is contraindicated in
severe heart failure.
The benefits of dronedarone in atrial fibrillation were
60 comprehensively demonstrated in the ATHENA (a placebo-
controlled, parallel arm trial to assess the efficacy of dronedar-
one 400 mg b.i.d. for the prevention to cardiovascular
hospitalization or death from any cause in patients with atrial
fibrillation/atrial flutter) trial. This trial showed that drone-
65 darone reduced the composite outcome of hospitalization
due to cardiovascular events or death in subjects with
intermittent atrial fibrillation or flutter [7].
Recently, dronedarone has been investigated in subjects
with high-risk permanent atrial fibrillation, but not severe
70 heart failure, in the PALLAS (permanent atrial fibrillation
outcome study using dronedarone on top of standard therapy)
study, and was shown to be detrimental [8]. PALLAS is the
subject of this evaluation.
2. PALLAS
75 2.1 Introduction
The Phase IIIb PALLAS trial was instigated to investigate the
potential value of dronedarone in a patient population different
to that supported by the recommendations that arose following
the conclusions of the ATHENA study [8]. PALLAS was to be a
80 large-scale, randomized, placebo-controlled, double-blind
study involving 489 sites globally which would establish
whether or not dronedarone would reduce major vascular
events or unplanned hospitalization for cardiovascular causes
in patients with permanent atrial fibrillation or flutter [8].
85 2.2 Methods and results
The methods and results of PALLAS [8], showing that drone-
darone was detrimental in permanent atrial fibrillation are
summarized here. Study participants were selected from
patients of 65 years or older, with documented permanent
90 atrial fibrillation (for at least 6 months) for whom there was
no treatment plan to restore sinus rhythm. Patients also
needed to possess one or more additional risk factors from:
coronary artery disease, history of stroke or transient ischae-
mic attack, symptomatic heart failure (New York Heart Asso-
95 ciation, NYHA, class II or III), LVEF of £ 40%, peripheral
artery disease, or a combination of age > 75 years with hyper-
tension/diabetes. Subjects with excessively prolonged QTc
intervals were excluded from the study, as were those with
paroxysmal or persistent atrial fibrillation, with implantable
100cardioverter-defribrillators, or with sustained daytime brady-
cardia. Previous/existing drug treatment was not a cause for
exclusion, with the exception of drugs known to prolong the
QT interval; however, digoxin was to be used only with
caution and close monitoring of serum concentrations [8].
105The subjects enrolled had a mean age of 75 years and were
predominantly male (~ 65%). Most were enrolled because
they had coronary artery disease (~ 41%), followed by previ-
ous stroke or transient ischaemic attack (~ 27%), and
age ‡ 75 years plus hypertension and diabetes (~ 17%).
110Many of the enrolled (~ 69%) had had permanent atrial
fibrillation for more than 2 years. The most common stage
of heart failure among the enrolled was NYHA class II
(~ 45 -- 46%) followed by class I (~ 13 -- 14.5%) and class
III (~ 8 -- 9%), although about 32% had no history of heart
115failure. Most of the subjects were taking a vitamin K antago-
nist (84%) and drugs for hypertension or heart failure.
Subjects (3236) were assigned to additional dronedarone
treatment to receive either dronedarone 400 mg twice daily
or matching placebo [8].
120Subject enrolment for PALLAS commenced in July of
2010. In July 2011, PALLAS was terminated on the basis of
a significantly increased incidence of cardiovascular events in
the group receiving dronedarone [9]. This evaluation is of
the results from PALLAS when it was stopped, which was
125with a median follow-up period of 3.5 months.
PALLAS had two primary outcome measures. The first of
these was a composite of stroke, myocardial infarction, embo-
lism (systemic) or death from cardiovascular causes (including
arrhythmia, heart failure, stroke and other vascular events).
130This outcome had occurred in 19/1617 subjects on placebo,
compared with 43/1619 on dronedarone (p = 0.002). Deaths
in the dronedarone group were nearly two-fold those in the
placebo group (25 vs 13, p = 0.046), of which a significant
proportion (13 vs 4, p = 0.03) were associated with arrhyth-
135mia. Stroke occurrence was more than doubled with
dronedarone (23 vs 10, p = 0.02) [8].
The second primary outcome was unplanned hospitaliza-
tion for a cardiovascular cause or death, and this occurred in
67 patients on placebo versus 127 on dronedarone. This
140increase was mainly due to unplanned hospitalization due to
cardiovascular causes (59 versus 113 of which hospitalization
for heart failure or a heart failure-related episode occurred in
115 patients on dronedarone versus 55 on AQ4placebo. Subgroup
analysis (e.g., age, with and without heart failure, with and
145without the various risk factors, with and without the various
medications) showed the effects of dronedarone to be similar
across most subgroups, except in the case of the second
primary outcome for which patients with diabetes exhibited
a relatively higher risk [8].
150The effect of dronedarone on permanent atrial fibrillation
was minimal. Thus, at the 4-month visit, 1.4% of the placebo
group were in sinus rhythm and this was increased to 3.7% in
the dronedarone group. Dronedarone reduced heart rate by
8 beats/min and systolic blood pressure by 3.5 mmHg [8].
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155 2.3 Discussion
The discussion of the PALLAS trial is summarized here. The
authors discuss that in ANDROMEDA it was assumed that
the deaths in subjects on dronedarone were due to heart
failure and were suggestive of a negative inotropic effect of
160 dronedarone, whilst in ATHENA hospitalization for heart
failure was decreased [8].
The authors do not have an explanation for the increased
risk of stroke or cardiac arrhythmia with dronedarone in
PALLAS and point out that both of these parameters were
165 improved by dronedarone in ATHENA [8]. However, they
do suggest that as dronedarone inhibits multiple ion channels,
it may be related to this [8].
The authors suggest that differences between ATHENA
and PALLAS in unplanned hospitalization (decreases and
170 increases, respectively) may be explained, at least in part, by
the higher age (75 vs 72 years) and greater propensity of
patients in the PALLAS study to have a history of stroke or
other cardiovascular disease [8].
A feature of the PALLAS population that was commented
175 on by the study investigators is the fact that nearly one-
third of subjects received digoxin, and dronedarone produced
a moderate (33%) increase in serum digoxin [8]. As digoxin
has previously been shown to increase death from cardiovas-
cular causes not related to heart failure, this may have been
180 a contributing factor [8].
3. Expert opinion
3.1 Rationale for PALLAS
The rationale given by Connolly et al., for PALLAS, was that
subjects with permanent atrial fibrillation are at high risk of
185 the same type of cardiovascular events as seen in intermittent
atrial fibrillation in ATHENA [8]. Analysis of an ATHENA
subgroup of patients, in whom all ECGs performed during
the study showed atrial fibrillation or flutter, found two
strokes in those receiving dronedarone compared with eight
190 on placebo [10]. A subsequent abstract has also reported that
dronedarone was effective in subjects with permanent atrial
fibrillation from ATHENA [11]. The mechanism for this ben-
efit in permanent atrial fibrillation was not closely associated
with restoration of sinus rhythm, but the other mechanisms
195 of dronedarone (slowing heart rate, reducing blood pressure,
adrenoceptor blockade, and suppression of ventricular fibrilla-
tion) may have contributed to the benefit [8]. Thus, it was
hypothesized that dronedarone may be effective in permanent
atrial fibrillation [8].
200 The standard dogma about clinical trials is that they are
only true for the dose of drug tested in the medical condition
tested. Thus, strictly speaking the conclusions of ATHENA
hold only for dronedarone 400 mg twice a day in subjects
with paroxysmal or persistent atrial fibrillation when drug
205 treatment is commenced. Most of the analysis and subgroup
analysis of ATHENA has been on subjects with intermittent
atrial fibrillation and so cannot readily be extrapolated
directly to patients with permanent atrial fibrillation. Those
ATHENA subjects with ‘permanent’ fibrillation were patients
210for whom ECGs taken during the study showed atrial fibrilla-
tion or flutter [11], and it is possible that conclusions from sub-
group analysis on such individuals may not apply to subjects
with well-established permanent atrial fibrillation before
study commencement, as occurred in PALLAS. Certainly,
215the outcomes of PALLAS demonstrate that propositions for
dronedarone benefit in permanent atrial fibrillation based
on ATHENA subgroup analysis have not held, when tested
on the large sample patient groups studied in PALLAS.
Arguably, the findings from ATHENA regarding ‘permanent’
220atrial fibrillation could have been pursued usefully in a new
Phase IIb trial focusing on patients with established perma-
nent atrial fibrillation (i.e., similar in this regard to PALLAS
subjects), but with characteristics otherwise similar to those
of subjects enrolled in ATHENA. However, the negative
225results of PALLAS make it unlikely that such a Phase IIb
study would now be undertaken.
There is some previous peer-reviewed evidence to support
the use of dronedarone in permanent atrial fibrillation. In
ERATO (efficacy and safety of dronedarone for the control
230of ventricular rate during atrial fibrillation), dronedarone
decreased ventricular rate in subjects with permanent atrial
fibrillation [12]. This trial used 24-h Holter monitoring on
day 0, day 14 and at 4 months, and did not show any proar-
rhythmia effects with dronedarone [12]. However, it should
235be noted that the subjects in ERATO were younger (mean
age 65 years) and only had to have had permanent atrial
fibrillation for > 6 months, and maybe not at as high a cardio-
vascular risk as in PALLAS, though they did have significant
comorbidities. As ERATO only enrolled 174 subjects
240with permanent atrial fibrillation (89 of whom received
placebo and 85 dronedarone), it was not powered to measure
cardiovascular morbidity and mortality outcomes with drone-
darone. Nevertheless, the data from ERATO are probably
sufficient to support a Phase III trial of dronedarone in
245permanent atrial fibrillation.
The progression from paroxysmal/persistent to permanent
atrial fibrillation is associated with structural and electrical
atrial remodelling and increased risk of adverse events [1,2].
The longer the duration of fibrillation, the more difficult it
250becomes to restore normal sinus rhythm [1,2]. Clearly a major
difference between PALLAS and ATHENA is that patients in
PALLAS were not in sinus rhythm either when dronedarone
treatment was commenced or throughout dronedarone treat-
ment. However, it is unclear at this stage as to whether and,
255if so, by what mechanism(s) the lack of sinus rhythm per se
influenced overall cardiovascular outcome in those receiving
dronedarone compared with placebo.
3.2 Liver function test
In PALLAS, liver function was assessed by measuring alanine
260aminotransferase and bilirubin levels at each study visit. After
January 2011, these tests were done monthly for 6 months,
PALLAS: limiting indications for dronedarone in AF?
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and every 2 months for the remainder of the first year. Pre-
sumably, these extra liver function tests were initiated shortly
after reports of severe liver damage and hepatic failure on dro-
265 nedarone, with two elderly patients on the drug requiring liver
transplants [13]. Recent data have demonstrated differential
effects of amiodarone and dronedarone on liver mitochon-
drial function, suggestive of uncoupled oxidative phosphory-
lation, but not oxidative damage or impaired bioenergetics
270 with dronedarone [14]. Whilst liver function tests conducted
during PALLAS indicated some increase in abnormal liver
function on dronedarone compared with placebo, severe liver
damage was not reported in that study [8]. Nonetheless,
the FDA recommends monitoring liver enzymes, especially
275 during the first 6 months of treatment [13].
3.3 Anticoagulants
The vitamin K antagonists, particularly warfarin are well
known to decrease the incidence of stroke in subjects with
atrial fibrillation. In PALLAS, at baseline those patients allo-
280 cated to the dronedarone arm of the trial had similar
CHADS2 (stroke risk prediction) scores to those allocated to
the placebo arm. The trial found that the time in the thera-
peutic INR (international normalized ratio) was significantly
lower in those receiving dronedarone (55.6%) than in the pla-
285 cebo group (58.6%), but the authors argue that this is too
small a difference to be the cause of the doubling of stroke [8].
However, it does indicate that both groups were not optimally
managed with warfarin, and it is possible that this may have
been a contributory factor to the overall result.
290 3.4 Heart failure and vascular disease
In PALLAS at baseline ~ 32% of patients in the dronedarone
treatment group had no history of heart failure, whilst the
majority of the remaining ~ 68% of the patients who were
in heart failure were at NYHA stages I and II. Moreover,
295 only ~ 21% of patients in the dronedarone group had an
LVEF of £ 40%, whilst a previous study [15] had found that
in patients in sinus rhythm with compensated NYHA class I
and II heart failure and an LVEF of £ 30%, dronedarone
treatment for 30 days did not decrease LVEF. In his commen-
300 tary on PALLAS [16], Nattel noted that, whilst the extent of
systolic dysfunction in PALLAS patients was not particularly
severe, one marked difference between ATHENA and PAL-
LAS is the incidence of heart failure in the patient
population: ~ 67 -- 68% of patients in PALLAS had class
305 I -- III heart failure, with ~ 54% having class II -- III heart fail-
ure [16]. By comparison, in ATHENA only ~ 21% of patients
had class II -- III heart failure [16]. In this respect, PALLAS is
intermediate between ATHENA and ANDROMEDA (in
which nearly all patients had at least class II -- III heart
310 failure) [6,7,16]. The risk of cardiac and arrhythmic death for
atrial fibrillation patients with a history of heart failure has
previously been reported to be exacerbated by antiarrhythmic
medication [17]. PALLAS is also intermediate between
ATHENA and ANDROMEDA in terms of incidence of
315coronary vascular disease (ATHENA 30%, PALLAS 41%;
ANDROMEDA 65%) [16].
3.5 Post-PALLAS recommendations on
dronedarone use
It was highlighted in an editorial commentary accompanying
320the PALLAS report that there is no reason for subjects in per-
manent atrial fibrillation to receive antiarrhythmic drug treat-
ment [16], and a clear outcome from the PALLAS study is that
dronedarone should not be given to patients with permanent
atrial fibrillation. Thus, in December 2011, the FDA released
325notification of revision of the dronedarone drug label, recom-
mending that, whilst dronedarone is (still) indicated to reduce
hospitalization for atrial fibrillation in patients with non-
permanent atrial fibrillation, it must not be given to patients
with permanent atrial fibrillation [18]. This notification also
330indicated that patients prescribed Multaq should be given
concurrent appropriate antithrombotic therapy and regular
ECG monitoring and noted the potential to discontinue dro-
nedarone should atrial fibrillation arise in patients receiving
the drug [18].
335Atrial fibrillation commonly coexists with heart failure.
Thus, as dronedarone increases deaths in subjects with poorly
compensated class III or IV heart failure [6], its use in atrial
fibrillation is already limited. The results of PALLAS have
demonstrated that in the setting of permanent atrial fibrilla-
340tion the deleterious effects of heart failure are likely to be
worsened on dronedarone. However, the practical consequen-
ces of worsened outcomes for heart failure patients in
PALLAS may be more wide-ranging than the permanent
atrial fibrillation setting, at least until the underlying reasons
345for this aspect of PALLAS become clear. Indeed, in September
2011, following the termination of PALLAS in July, the
EMEA recommended restricting the use of dronedarone to
maintaining sinus rhythm after successful cardioversion of
paroxysmal or persistent atrial fibrillation [19]. It also recom-
350mended: that the drug be used only after other antiarrhythmic
drugs have been considered, that it not be given to patients
with heart failure or left ventricular dysfunction, that
physicians should consider discontinuing the drug should
atrial fibrillation recur, that it should not be given to any
355patient who had already experienced hepatic or lung injury
with previous amiodarone treatment and that patients on
dronedarone must undergo regular monitoring of liver func-
tion and cardiac rhythm [19]. Thus, in Europe at least drone-
darone is now likely to be a second-line pharmacological
360treatment for non-permanent atrial fibrillation in patients
without heart failure. Indeed, considering the collective out-
comes of ANDROMEDA and those of PALLAS, it is difficult
at the moment to see a clear context that would warrant
administration of dronedarone to patients with heart failure.
3653.6 Conclusions
The discontinuity between the findings of ATHENA and
PALLAS in respect of dronedarone use in intermittent and
S. A. Doggrell & J. C. Hancox
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permanent atrial fibrillation is remarkable. The principal out-
come of PALLAS is to demonstrate that dronedarone should
370 not be used in permanent atrial fibrillation and that it is also
probably unsuitable for intermittent atrial fibrillation patients
with a history of heart failure. The currently available informa-
tion suggests that, with close adherence to updated recommen-
dations, dronedarone may still have utility for patients with
375 non-permanent atrial fibrillation who are without heart
failure or left ventricle dysfunction. Recent post hoc analysis of
ATHENA data highlight the utility of dronedarone for rate
and rhythm control in that study population of patients
with intermittent atrial fibrillation and that the likelihood of
380permanent atrial fibrillation or flutter was lower on dronedar-
one than on placebo [20]. At this stage, it is probably fair to
conclude that PALLAS has raised more questions than answers
in terms of underlying mechanisms of increased risk and
that more work is clearly required to understand the basis of
385increased mortality with dronedarone in the setting of
permanent atrial fibrillation.
Declaration of interest
The authors state AQ5no conflict of interest and have received no
payment in preparation of this manuscript.
Bibliography
1. Rosenthal L, McManus DD. Atrial
fibrillation. Available from: http://
emedicine.medscape.com/article/151066-
print [Last accessed 30 December 2011]
2. Nattel S. New ideas about atrial
fibrillation 50 years on. Nature
2002;415:219-26
3. European Heart Rhythm Association;
European Association for
Cardio-Thoracic Surgery. Camm AJ,
et al. Guidelines for the management of
atrial fibrillation: the Task Force for the
Management of Atrial Fibrillation of the
European Society of Cardiology (ESC).
Eur Heart J 2010;31:2369-429
4. Zimetbaum P. Amiodarone for atrial
fibrillation. N Engl J Med
2007;356:935-41
5. Doggrell SA, Hancox JC. Dronedarone:
an amiodarone analogue. Expert Opin
Investig Drugs 2004;13:415-26
6. Køber L, Torp-Pedersen C,
McMurray JJV, et al. Increase mortality
after dronedarone therapy for severe heart
failure. N Engl J Med 2008;358:2678-87
7. Hohnloser SH, Crijns HJ,
van Eickels M, et al. Effects of
dronedarone on cardiovascular events in
atrial fibrillation. N Engl J Med
2009;360:668-78
8. Connolly SJ, Camm J, Halperin JL,
et al. Dronedarone in high-risk
permanent atrial fibrillation. N Engl
J Med 2011;365:2268-76
9. Sanofi provides Multaq Phase IIIb
PALLAS Trial Update. Available from:
http://en.sanofi.com/Images/
28473_20110707_PALLAS_en.pdf [Last
accessed 19 January 2012]
10. Connolly SJ, Crijns HJ,
Torp-Pedersen C, et al. Analysis of
stroke in ATHENA:
a placebo-controlled, double-blind,
parallel-arm trial to assess, the efficacy of
dronedarone 400 mg BID for the
prevention of cardiovascular
hospitalization or death from any cause
in patients with atrial fibrillation/atrial
flutter. Circulation 2009;120:1174-80
11. Nieuwlaat R, Hohnloser SH,
Connolly SJ. Effect of dronedarone in
patients with permanent atrial flutter
during the ATHENA study [abstract].
Eur Heart J 2011;32(Suppl):618
12. Davy JM, Herold M, Hoglund C, et al.
Dronedarone for the control of
ventricular rate in permanent atrial
fibrillation: the efficacy and safety of
dronedarone for the control of
ventricular rate during atrial fibrillation
(ERATO) study. Am Heart J
2008;156:527.e1-9
13. FDA Drug Safety Communication:
Severe liver injury associated with the use
of dronedarone (marketed as Multaq).
Available from: http://www.fda.gov/
drugs/drugsafety/ucm240011.htm [Last
accessed 19 January 2012]
14. Seviddio G, Bellanti F, Giudetti AM.
Mitochondrial oxidative stress and
respiratory chain dysfunction account for
liver toxicity during amiodarone but not
dronedarone administration. Free Radic
Biol Med 2011;51:2234-42
15. Levine TB, Giles T, Radzik E, Gali JK.
Effect of dronedarone on exercise
capacity and cardiac function in patients
with severe left ventricular dysfunction
and compensated stable heart failure.
Cardiovasc Drug Ther 2010;24:449-58
16. Nattel S. Dronedarone in atrial
fibrillation -- Jekyll and Hyde. N Engl
J Med 2011;365:2321-2
17. Flaker GC, Blackshear JL, McBride R,
et al. Antiarrhythmic drug therapy and
cardiac mortality in atrial fibrillation.
J Am Coll Cardiol 1992;20:527-32
18. FDA safety announcement re
dronedarone labelling changes. Available
from: http://www.fda.gov/Drugs/
DrugSafety/ucm283933.htm [Last
accessed 15 January 2012]
19. EMA Sept 2011. Revised dronedarone
guidelines/restrictions. Available from:
http://www.ema.europa.eu/docs/en_GB/
document_library/Press_release/2011/09/
WC500112800.pdf [Last accessed
15 January 2012]
20. Page RL, Connolly SJ, Crijns HJ, et al.
Rhythm- and rate-controlling effects of
dronedarone in patients with atrial
fibrillation (from the ATHENA trial).
Am J Cardiol 2011;107:1019-22
Affiliation
Sheila A Doggrell†1 PhD DSc &
Jules C Hancox2 PhD FSB
†Author for correspondence
1Queensland University of Technology,
School of Biomedical Sciences,
Faculty of Health,
Brisbane, QLD 4001, Australia
Tel: + 61 7 3138 2015;
Fax: + 61 7 3138 1534;
E-mail: sheila.doggrell@qut.edu.au
2University of Bristol,
School of Physiology and Pharmacology,
AQ3Bristol, UK
PALLAS: limiting indications for dronedarone in AF?
Expert Opin. Pharmacother. (2012) 13(06) 5
